East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Bupropion Hydrochloride Extended-Release Tablets USP (XL), 150 mg and 300 mg. Aurobindo Pharma’s Bupropion Hydrochloride Extended-Release Tablets USP (XL),  are an AB-rated generic equivalent to the reference listed drug (RLD), Wellbutrin XL® Extended-Release Tablets, manufactured by Bausch Health US, LLC,.

Bupropion Hydrochloride Extended-Release Tablets USP (XL) are indicated for the:

• Treatment of major depressive disorder (MDD).
• Prevention of seasonal affective disorder (SAD).